RoActemra for Clinical Trials

Actemra/RoActemra is approved in 116 nations for rheumatoid arthritis (RA). The drug is also approved for systemic juvenile idiopathic arthritis (sJIA), pediatric juvenile idiopathic arthritis (pJIA), CAR-T cell-induced cytokine release syndrome (CRS), and giant cell arteritis (GCA). This medicinal product is available in both intravenous (IV) and subcutaneous (SC) formulations.

Actemra/RoActemra is a first-in-class aIL-6R therapy, believed to play a significant role in activating the inflammatory pathway that causes signs and symptoms of rheumatoid arthritis and other inflammatory autoimmune complications. It binds to IL-6 receptors, inhibiting the pro-inflammatory consequences of IL-6 cytokines.

The medicine is approved for defined patients hospitalized with serious or critical COVID-19 in different territories including Japan, European Union (EU), Ecuador, Peru, Honduras, Myanmar, Ukraine, and the UK. It is provisionally approved in Australia and is authorized for emergency use in the US and Ghana. It has also been recommended by the specialized agency of the UNs responsible for international public health named WHO.

Several studies have assessed the efficacy and safety of Actemra/RoActemra. The UN agency has also reported that IL-6 receptor inhibitors, such as Actemra/RoActemra, are expected to still be promising against the SARS-CoV-2 variant of concern, Omicron (B.1.1.529).

Would you like to order reference listed products such as roactemra for clinical trials and analytical purposes in the most convenient way? We can help to procure the necessary innovator product samples and the relevant drug product information in a prompt and efficient way.

We are always looking to support clinical trials for Roactemra in India, European countries, and the USA, and the development of generic medicines to ensure the global market access and enhance patient availability to treatment therapies globally by aiding manufacturers with the sourcing and supply of reference samples for clinical trials and research purposes.

We offer a wide range of services including reference listed drugs (RLDs) sourcing or innovator products sample supply. Our experience as pharmaceutical Wholesalers/Distributors/Suppliers combined with the international network of partners make us a leader in the industry. Direct relationships with certified and reliable manufacturers allow us to supply to the specific location while maintaining top-notch product integrity and GDP practices.

We provide global access to reference products (RLDs, reference listed drugs) with complete service from sourcing to delivery. We supply these hard-to-find drug products in both large and small quantities.If you want to source Reference Listed Drug’s such as Roactemra from USA , South Korea , Japan or EU countries for clinical trial studies kindly do get in touch with us. You can send your enquiry at info@ikrispharmainternational.com or Dial our TOLL-FREE: 1800-889-1064 number for further assistance